C. Bennett
Chief Tech/Sci/R&D Officer chez IONIS PHARMACEUTICALS, INC.
Fortune : 3 M $ au 31/03/2024
Profil
C. Frank Bennett occupe le poste de Chief Scientific Officer & Executive VP chez Ionis Pharmaceuticals, Inc. Le Dr Bennett a obtenu un diplôme de premier cycle à l'Université du Nouveau-Mexique et un doctorat au Baylor College of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
29/02/2024 | 79 462 ( 0,05% ) | 3 M $ | 31/03/2024 |
Postes actifs de C. Bennett
Sociétés | Poste | Début |
---|---|---|
IONIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
Hereditary Disease Foundation | Corporate Officer/Principal | - |
Anciens postes connus de C. Bennett
Sociétés | Poste | Fin |
---|---|---|
PERCHERON THERAPEUTICS LIMITED | Director/Board Member | 10/03/2008 |
Smithkline & French Laboratories US, Inc. | Corporate Officer/Principal | - |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Director/Board Member | - |
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Director/Board Member | - |
Formation de C. Bennett
The University of New Mexico | Undergraduate Degree |
Baylor College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
PERCHERON THERAPEUTICS LIMITED | Health Technology |
Entreprise privées | 4 |
---|---|
Smithkline & French Laboratories US, Inc. | |
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Distribution Services |
Hereditary Disease Foundation | |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |